Utilization of Biosimilars in Retinal Diseases

home / insights / utilization-of-biosimilars-in-retinal-diseases

Dr Peter Kaiser, an ophthalmologist, provides an overview of biosimilars, the regulatory pathway for their approval, and how biosimilars can aid in providing quality care to patients. Dr. Kaiser shares data with ranibizumab biosimilars in ophthalmology and discusses key differences between biosimilar and reference product studies.

© 2024 MJH Life Sciences

All rights reserved.